Format

Send to

Choose Destination
J Am Acad Dermatol. 2017 Jun;76(6):1054-1060.e1. doi: 10.1016/j.jaad.2017.02.049. Epub 2017 Apr 5.

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib.

Author information

1
Department of Dermatology, Tufts Medical Center, Boston, Massachusetts.
2
Department of Dermatology, Newton Wellesley Hospital, Newton, Massachusetts.
3
Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
4
Department of Dermatology, Tufts Medical Center, Boston, Massachusetts; Department of Dermatology, New York Medical College, Valhalla, New York.
5
Department of Dermatology, Tufts Medical Center, Boston, Massachusetts. Electronic address: DRosmarin@tuftsmedicalcenter.org.

Abstract

BACKGROUND:

Existing therapies for vitiligo are limited in efficacy and can be associated with undesirable side effects. Topical Janus kinase inhibitors may offer a new therapeutic option for vitiligo.

OBJECTIVE:

We sought to assess the role of topical ruxolitinib 1.5% cream, a Janus kinase inhibitor, in vitiligo treatment.

METHODS:

This 20-week, open-label, proof-of-concept trial of twice-daily topical ruxolitinib 1.5% cream was conducted in 12 patients with a minimum of 1% affected body surface area of vitiligo. The primary outcome was percent improvement in Vitiligo Area Scoring Index from baseline to week 20.

RESULTS:

Of 12 patients screened, 11 were enrolled and 9 completed the study (54.5% men; mean age, 52 years). Four patients with significant facial involvement at baseline had a 76% improvement in facial Vitiligo Area Scoring Index scores at week 20 (95% confidence interval, 53-99%; P = .001). A 23% improvement in overall Vitiligo Area Scoring Index scores was observed in all enrolled patients at week 20 (95% confidence interval, 4-43%; P = .02). Three of 8 patients responded on body surfaces and 1 of 8 patients responded on acral surfaces. Adverse events were minor, including erythema, hyperpigmentation, and transient acne.

LIMITATIONS:

Limitations of the study include the small sample size and open-label study design.

CONCLUSIONS:

Topical ruxolitinib 1.5% cream provided significant repigmentation in facial vitiligo and may offer a valuable new treatment for vitiligo.

KEYWORDS:

Janus kinase inhibitor; VASI; facial vitiligo; ruxolitinib; topical application; vitiligo

PMID:
28390737
DOI:
10.1016/j.jaad.2017.02.049
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center